London’s blue-chip index closed Friday’s session 0.51% lower as investors digested a wave of UK economic data painting a mixed picture of the British economy. The GfK Consumer Confidence Barometer dropped sharply
Estate planning involves choosing between key legal tools, and understanding how a will differs from a revocable trust is essential for making the right decision. Both documents direct how your assets will
More
Health law is emerging as one of the most dynamic and in-demand practice areas for law students entering the profession today. As the healthcare industry continues its rapid expansion, demand for lawyers
More
Markets have delivered another strong year in 2026, with the FTSE 100 up 8.5% and the S&P 500 gaining 11.1% year to date, both before dividends. The tech-heavy Nasdaq-100 has outpaced both
More
Market crashes are an inevitable feature of investing, arriving without warning and testing the resolve of even the most experienced investors. History has shown repeatedly that stock markets do not rise in
More
B. Braun Medical has initiated a recall of a single lot of Excel lactated ringers injection across the United States and Canada due to particulate contamination concerns. The recall affects product shipped
More
Proskauer Rose LLP has received the President’s Award from the National Association of Counsel for Children, recognising the firm’s commitment to justice in a landmark child welfare case. The award was presented
More
The legal profession is facing fresh questions about whether law schools should be doing more to equip graduates with knowledge of how the human brain makes decisions. One proposal gaining attention is
More
City analysts are pointing to two FTSE 100 names as standout opportunities, with potential upside of at least 30% over the next 12 months. JD Sports Fashion and London Stock Exchange Group
More
Oxford Nanopore Technologies posted strong gains on the London Stock Exchange, emerging as one of the standout performers across the FTSE 250 index. The genomics and sequencing technology company has attracted renewed
More
Xspray Pharma has received yet another Complete Response Letter from the U.S. Food and Drug Administration, further delaying approval of its leukemia drug candidate Dasynoc. The setback marks the latest in a
More